TABLE 1.

Patient characteristics, treatments, COVID‐19‐related outcomes as well as additional laboratory and clinical data

Pat. ID	1	2	3	4	5	6	7	8	9
Patient characteristics, treatments and COVID‐19 related outcomes
Diagnosis	MM	MM	MM	MM	MM	MM	MM	MM	SMM
Age, y	58	77	70	70	43	83	94	71	68
Gender	M	M	F	M	F	F	M	M	M
Sub‐type	IgAλ	κ	IgAλ	IgGκ	IgAκ	IgAλ	IgDλ	IgGκ	IgGλ
ISS a	III	III	III	II	—	II	III	—	II
Previous lines of MM treatment	5 b	0	4 c	0	1 d	1 e	0	1 f	—
Current line of MM treatment	dD‐Veneto	dVD	dD	dRD	dKD	dD	RD	RD	None
Months on current MM treatment	2	3	7	49	5	16	3	17	—
MM response to current line	PD	PD	MR	CR	VGPR	VGPR	PR	VGPR	—
MM disease progression	Yes	Yes	No	No	No	No	No	No	No
COVID‐19 related risk factors	DM2	No	No	No	DM2, HT	DM2, HT	DM2	No	HT
BMI	30	23	20	21	24	34	25	24	23
Anticoagulants	No	No	No	Yes	No	No	Yes	Yes	No
Death due to COVID‐19	Yes	Yes	No	No	No	No	Yes	Yes	No
Laboratory values at verification of COVID‐19 (PCR)
CRP, mg/L	79	16	38	136	<1	65	—	6	—
Hemoglobin, g/dL	71	104	93	100	112	100	114	132	126
Leukocytes, 109/L	1.2	10.5	6.1	4.9	2	4.3	4	1.8	5.2
Neutrophils, 109/L	0.5	8	—	4.5	—	3.2	—	1.4	—
Lymphocytes, 109/L	0.5	—	—	0.3	—	0.7	—	0.2	—
Creatinine, μmol/L	102	47	68	60	55	116	72	83	118
eGFR, mL/min/1.73 m2	63	>90	>90	78	>90	37	60	67	51
M‐protein spike, g/L	68	—	16	0	1	2	—	1	54
IgG, g/L	1.8	2.2	0.83	5	3.0	4.9	5.7	8.1	0
IgA, g/L	0	<0.08	0	0.42	1.1	0.30	2.1	2.5	0.23
IgM, g/L	<0.1	<0.08	<0.1	0.96	<0.1	0.24	0.34	0.39	0.21
Immunoparesis g	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes
Clinical symptoms in the course of COVID‐19
Fever, >38.5°C	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dry cough	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Dyspnoea	Yes	No	No	No	No	Yes	Yes	No	np
Other COVID‐19 related symptoms h	No	No	No	Yes	Yes	No	No	Yes	No
Saturation, lowest level	93%	ND	ND	95% i	ND	89%	79%	70%	ND
Oxygen demanding	No	No	No	Yes	No	Yes	Yes	Yes	No
Hospitalization	No j	No j	No k	Yes	No k	Yes	Yes l	Yes	No k
PCR and COVID‐19 specific IgG response
Post‐COVID‐19‐positive PCR, d	NE	NE	ND	34	28	10	NE	NE	7
IgG antibody response to COVID‐19, d	NE	NE	ND	46 (pos)	15 (neg)	10 (neg)	NE	NE	78 (neg)

Abbreviations: CR, complete response; dD, (daratumumab‐dexamethasone); dD‐Veneto, (daratumumab‐dexamethasone‐venetoclax); dKD, (daratumumab‐carfilzomib‐dexamethasone); DM2, Diabetes mellitus type 2; dRD, (daratumumab‐lenalidomide‐dexamethasone); dVD, (daratumumab‐bortezomib‐dexamethasone); HDT, (high‐dose treatment); HT, hypertension; KD, (carfilzomib‐dexamethasone); KPD, (carfilzomib‐pomalidomide‐dexamethasone); MR, minimal response; ND, not determined; NE, not evaluable due to exitus; PD, (pomalidomide‐dexamethasone); PD, progressive disease; PR, partial response; RD, (lenalidomide‐dexamethasone); VCD, (bortezomib‐cyclophosphamide‐dexamethasone); VGPR, very good partial response; VRD, (bortezomib‐lenalidomide‐dexamethasone); VTD, (bortezomib‐thalidomide‐dexamethasone).

^a As defined by the International Myeloma Working Group.

^b 1st line VCD + HDT 2nd line RD 3rd line KPD 4th line dD 5th HDT.

^c 1st line VTD 2nd line RD 3rd line PD, 4th line KD.

^d 1st line VRD + HDT.

^e 1st line VCD.

^f 1st line VCD.

^g Reduction below the lower normal limit of one or two uninvolved immunoglobulins, IgG < 6.7 g/L, IgA < 0.88 g/L, IgM < 0.27 g/L.

^h Either of diarrhea, arthralgia, loss of taste.

ⁱ Saturation on 5 L oxygen.

^j Hospitalization was judged not to be beneficial, because of end‐stage disease.

^k Mild symptoms, admission to hospital not required.

^l Received oxygen treatment at home from advanced homecare teams.